Currently, Verona Pharma Plc ADR [VRNA] is trading at $72.58, up 1.78%. An important factor to consider is whether the stock is rising or falling in short-term value. The VRNA shares have gain 7.48% over the last week, with a monthly amount glided 23.18%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Verona Pharma Plc ADR [NASDAQ: VRNA] stock has seen the most recent analyst activity on April 28, 2025, when TD Cowen initiated its Buy rating and assigned the stock a price target of $100. Previously, Cantor Fitzgerald started tracking the stock with Overweight rating on April 21, 2025, and set its price target to $80. On January 10, 2025, ROTH MKM initiated with a Buy rating and assigned a price target of $68 on the stock. Wells Fargo started tracking the stock assigning a Overweight rating and suggested a price target of $50 on October 03, 2024. In a note dated August 26, 2022, Piper Sandler initiated an Overweight rating and provided a target price of $31 on this stock.
This stock has fluctuated between a low of $11.39 and a high of $74.18 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $78 within the next 12 months. Verona Pharma Plc ADR [NASDAQ: VRNA] shares were valued at $72.58 at the most recent close of the market. An investor can expect a potential return of 7.47% based on the average VRNA price forecast.
Analyzing the VRNA fundamentals
Gross Profit Margin for this corporation currently stands at 0.95% with Operating Profit Margin at -1.16%, Pretax Profit Margin comes in at -1.31%, and Net Profit Margin reading is -1.38%. To continue investigating profitability, this company’s Return on Assets is posted at -0.31, Equity is -0.9 and Total Capital is -0.29. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Verona Pharma Plc ADR [NASDAQ:VRNA] is 8.86. On the other hand, the Quick Ratio is 8.73, and the Cash Ratio is 7.1. Considering the valuation of this stock, the price to sales ratio is 52.12, the price to book ratio is 27.27.
Transactions by insiders
Recent insider trading involved Fisher Andrew, General Counsel, that happened on May 15 ’25 when 80000.0 shares were sold. Director, ACKERMANN CHRISTINA completed a deal on May 14 ’25 to sell 40000.0 shares. Meanwhile, Officer ANDREW FISHER bought 30000.0 shares on May 15 ’25.
